Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Pharmacokinetic Multi-tumor Study of Subcutaneous Formulation of Ipilimumab Monotherapy and in Combination With Subcutaneous Nivolumab

NCT04311710 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.

NCT NCT04311710
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04311710 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Pharmacokinetic Multi-tumor Study of Subcutaneous Formulation of Ipilimumab Monotherapy and in Combination With Subcutaneous Nivolumab
Lead sponsor
Bristol-Myers Squibb
Phase
Phase 1
Overall status
Terminated
Start date
June 25, 2020
Completion date
January 18, 2023
Enrollment
21 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

tumor